None
SEDAR Interim Financial Statements
MBI · Price
[
{
"companyName": "Many Bright Ideas Technologies Inc. (Formerly Med BioGene Inc.)",
"reportingPeriodEnd": "2025-09-30",
"reportStatus": "Unaudited",
"auditorName": null,
"auditorKeyMatters": [],
"balanceSheet": {
"cash": 1254,
"receivables": 279,
"prepaidExpenses": 4251,
"totalCurrentAssets": 5784,
"totalAssets": 5784,
"accountsPayableAndAccruedLiabilities": 40440,
"dueToRelatedParties": 177261,
"totalCurrentLiabilities": 217701,
"totalLiabilities": 217701,
"commonShares": 9280090,
"equityReserves": 5073703,
"deficitAccumulatedDuringDevelopmentStage": -14870093,
"accumulatedOtherComprehensiveIncome": 304383,
"totalDeficiency": -211917,
"totalLiabilitiesAndDeficiency": 5784,
"cashPerShare": 0.0001,
"workingCapitalPerShare": -0.0123
},
"incomeStatement": {
"threeMonthsEndedSep30_2025": {
"generalAndAdministrative": 9159,
"lossForPeriod": -9159,
"otherComprehensiveIncome": 4185,
"comprehensiveLoss": -4974,
"basicAndDilutedLossPerShare": -0.00,
"weightedAverageSharesOutstanding": 17257838
},
"threeMonthsEndedSep30_2024": {
"generalAndAdministrative": 10804,
"lossForPeriod": -10804,
"otherComprehensiveLoss": -1859,
"comprehensiveLoss": -12663,
"basicAndDilutedLossPerShare": -0.00,
"weightedAverageSharesOutstanding": 17257838
},
"nineMonthsEndedSep30_2025": {
"generalAndAdministrative": 37743,
"lossForPeriod": -37743,
"otherComprehensiveLoss": -5641,
"comprehensiveLoss": -43384,
"basicAndDilutedLossPerShare": -0.00,
"weightedAverageSharesOutstanding": 17257838
},
"nineMonthsEndedSep30_2024": {
"generalAndAdministrative": 40934,
"lossForPeriod": -40934,
"otherComprehensiveIncome": 2473,
"comprehensiveLoss": -38461,
"basicAndDilutedLossPerShare": -0.00,
"weightedAverageSharesOutstanding": 17257838
}
},
"cashFlowStatement": {
"nineMonthsEndedSep30_2025": {
"lossForPeriod": -37743,
"changesInAccountsPayableAndAccruedLiabilities": 1371,
"changesInReceivables": 326,
"changesInPrepaidExpenses": -2256,
"netCashUsedInOperatingActivities": -38302,
"dueToRelatedParties": 44317,
"netCashFromFinancingActivities": 44317,
"changeInCash": 374,
"cashBeginningOfPeriod": 880,
"cashEndOfPeriod": 1254
},
"nineMonthsEndedSep30_2024": {
"lossForPeriod": -40934,
"changesInAccountsPayableAndAccruedLiabilities": 9557,
"changesInReceivables": 163,
"changesInPrepaidExpenses": -5597,
"netCashUsedInOperatingActivities": -36811,
"dueToRelatedParties": 34556,
"netCashFromFinancingActivities": 34556,
"changeInCash": 218,
"cashBeginningOfPeriod": 713,
"cashEndOfPeriod": 931
}
},
"investmentsAndOtherAssets": [
{
"type": "Joint Venture",
"description": "Wholly owned subsidiary DTX Acquisition Company Inc.",
"ownershipPercentage": 100,
"value": null,
"notes": "Consolidated but no separate asset value shown on balance sheet"
},
{
"type": "Intellectual Property",
"description": "GeneFx Lung technology and related IP from University Health Network",
"ownershipPercentage": null,
"value": null,
"notes": "Previously commercialized through Helomics; now considered obsolete with no carrying value on balance sheet"
}
],
"shareStructure": {
"authorizedShares": "Unlimited",
"issuedShares": 17257838,
"classesOfShares": ["voting common shares"],
"warrants": [],
"options": [
{
"number": 350000,
"exercisePrice": 0.5,
"expiryDate": "2025-11-19"
},
{
"number": 750000,
"exercisePrice": 0.5,
"expiryDate": "2027-01-03"
}
],
"rightsConvertibleInstruments": null
},
"managementCompensation": {
"currency": "USD",
"periods": {
"Nine months ended September 30, 2025": {
"accountingFees": 6437
},
"Nine months ended September 30, 2024": {
"accountingFees": 6617
}
},
"namedIndividuals": [],
"otherRelatedPartyTransactions": [
{
"counterparty": "Officer of the Company",
"description": "Accounting fees",
"amount": 6437,
"period": "Nine months ended September 30, 2025"
},
{
"counterparty": "Former management and directors",
"description": "Amounts owing, non-interest bearing, due on demand",
"amount": 177261,
"period": "As at September 30, 2025"
}
]
},
"subsequentEvents": []
}
]